The Effect of Branched-chain Amino Acid (BCAA) on the Progression of Primary Liver Cancer

Tel-Aviv Sourasky Medical Center60 enrolled

Overview

Supplementation of BCAA found to reduce the risk of developing liver cancer, but the affect of BCAA on existing liver cancer is unknown. The participants (post curative intent surgery) will be supplemented with either BCAA/non-BCAA-enriched protein supplement. The intervantion will go on for 2 years or until a new liver tumor is found.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Masking

DOUBLE

Enrollment

Conditions

Primary Liver Cancer

Interventions

Branched-chain amoni acids (BCAA)DIETARY_SUPPLEMENT

non-BCAA protein supplementDIETARY_SUPPLEMENT

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * diagnosed primary liver cancer * viral or Nonalcoholic Steatohepatitis Cirrhosis * Cirrhosis rated Child-Pugh A * liver cancer rated Barcelona Clinic Liver Cancer (BCLC) A Exclusion Criteria: * Age (over 65) * liver condition rated Child-Pugh B/C * GI/Absorption issues * patients given a treatment before surgery

Locations (1)

Clinical Nutrition Unit, Sourasky Medical Center

Tel Aviv, Israel

Outcomes

Primary Outcomes

time until a new liver tumor is found

Time frame: 2 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.